Actively Recruiting
Efficacy and Safety of FEXUCLUE Tab. In Patients With Acute or Chronic Gastritis
Led by Daewoong Pharmaceutical Co. LTD. · Updated on 2025-07-17
12000
Participants Needed
1
Research Sites
102 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to evaluate the efficacy of Fexuclue tablets in improving gastrointestinal symptoms based on patient-reported outcomes (PROs), by comparing assessments before and after treatment.
CONDITIONS
Official Title
Efficacy and Safety of FEXUCLUE Tab. In Patients With Acute or Chronic Gastritis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult subjects between the ages of 19 and 75 years at the time of obtaining written informed consent.
- Subjects who are scheduled to receive Fexuclu tablets (fexuprazan) in accordance with the approved indication.
- Subjects who present with at least one subjective symptom requiring medical treatment
- Subjects who are capable of understanding the information provided, have voluntarily decided to participate in this observational study, and have provided written informed consent for the use of their personal data.
You will not qualify if you...
- Individuals who fall under any contraindications for the administration of Fexuclu tablets (fexuprazan) as specified in the approved labeling.
- Individuals who are deemed by the investigator (attending physician) to be inappropriate for participation in this observational study for any reason not otherwise specified.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Masong Kim Internal Medicine Clinic
Seoul, South Korea
Actively Recruiting
Research Team
S
So Heui Kim
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here